Lenalidomide in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma (NHL) in adults. Even if the natural history of DLBCL has been improved with the advent of immunochemotherapy, the survival results obtained with current treatment options clearly indicate that new agents or...
Saved in:
| Main Authors: | Catherine Thieblemont, Marie-Hélène Delfau-Larue, Bertrand Coiffier |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/861060 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenalidomide in Diffuse Large B-Cell Lymphomas
by: Annalisa Chiappella, et al.
Published: (2012-01-01) -
Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China
by: Rongqi Li, et al.
Published: (2024-12-01) -
Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma
by: Alexander Meisel, et al.
Published: (2025-03-01) -
Personalized medicine in diffuse large B-cell lymphoma
by: Prashant Mehta, et al.
Published: (2019-01-01) -
Diffuse large B-cell lymphoma misdiagnosed as cellulitis
by: Tamotsu Kuribayashi, et al.
Published: (2025-04-01)